The Role of Peptidyl-tRNA Hydrolase 2 in Maternal Cardiac Adaptation and Survival

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Nature Communications https://doi.org/10.1038/s41467-025-67852-9 
Dr. Vanessa Montoya-Uribe  et al.

Points

Scientists discovered that the PTRH2 gene acts as a critical molecular safeguard by activating pro-survival signals and blocking apoptosis to protect the maternal heart from severe pregnancy induced physiological stresses.
Maternal mice lacking the PTRH2 gene in cardiac tissue developed severe left ventricular systolic dysfunction and high rates of postpartum heart failure that modeled key clinical features of human peripartum cardiomyopathy.
Research observed that Ptrh2 protein levels naturally increase during pregnancy and decrease postpartum in healthy subjects which confirms its protective role in responding to the increased workload on the heart.
Infusing a caspase three specific inhibitor successfully attenuated the diseased phenotype in knockout models which suggests that preventing programmed cell death is a viable strategy for managing this life-threatening condition.
These findings provide a new framework for understanding dysregulated cardiac signaling during pregnancy and open doors for targeted precision therapies to improve survival rates among women affected by peripartum cardiomyopathy.

Summary

This study identifies the peptidyl-tRNA hydrolase 2 (PTRH2) gene as a critical molecular safeguard against peripartum cardiomyopathy (PPCM). In wild-type female mice, Ptrh2 protein levels significantly upregulate during pregnancy to mitigate cardiac stress, subsequently decreasing in the postpartum period. Researchers established that PTRH2 functions as a negative regulator of pregnancy-induced cardiac stress by activating pro-survival pathways and inhibiting pro-apoptotic signaling, thereby facilitating the physiological remodeling required to manage increased blood flow and cardiac workload during gestation.

To evaluate the impact of dysregulated signaling, a cardiac-specific Ptrh2 knockout (Ptrh2-CKO) mouse model was engineered. These maternal mice exhibited left ventricular systolic dysfunction and experienced high rates of postpartum heart failure, successfully recapitulating the key clinical features of human PPCM. Without the protective presence of PTRH2, the heart fails to return to normal dimensions postpartum, resulting in dangerous cardiac enlargement and systolic failure. The loss of PTRH2 effectively mirrors the genetic and molecular deficits seen in life-threatening pregnancy-related heart failure.

The research further explored potential interventions by infusing a caspase 3-specific inhibitor, which significantly attenuated the PPCM phenotype in the knockout models. These results suggest that PTRH2-mediated apoptotic regulation is a central mechanism in maternal heart health. These findings establish PTRH2 as a viable therapeutic target for the development of targeted treatments for PPCM, offering a novel clinical strategy to reduce mortality and improve recovery in affected postpartum populations by blocking apoptotic signals and promoting cellular survival.

Link to the article: https://www.nature.com/articles/s41467-025-67852-9

References

Montoya-Uribe, V., Choubey, P., Walton, C. B., Glibetic, N., Seok Yang, W., Aan, F. J., Lindsey, S., Peplowska, K., Hernandez, B. Y., Ramos, J. W., & Matter, M. L. (2025). Peptidyl-tRNA hydrolase 2 is a negative regulator of peripartum cardiomyopathy with heart failure in female mice. Nature Communications. https://doi.org/10.1038/s41467-025-67852-9